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The clinical utility of tender point (TP) examination in patients reporting chronic widespread pain (CWP) is the subject of
contemporary debate.The objective of this studywas to assess the relationship betweenmechanical hyperalgesia assessed bymanual
TP examination and clinical disease severity. 271 women with CWPwere recruited from a clinical setting. Data collection included
patient-reported symptoms, health-related quality of life variables, and observation-based measures of functional ability, muscle
strength, 6-minute walk, and pressure pain thresholds measured by cuff algometry. TP examination was conducted according to
ACR-guidelines. Relationships between disease variables andTP count (TPC)were analyzedwith logistic regression in a continuum
model, allowing the TPC to depend on the included disease variables and two regression models carried out for a TPC threshold
level, varying between 1 and 17. The threshold analyses indicated a TPC threshold at 8, above which a large number of disease
variables became consistently significant explanatory factors, whereas none of the disease variables reached a significance level in
the continuummodel. These results support the premise that the presence of mechanical hyperalgesia influences symptomatology
in CWP and that the severity of clinical expression is related to a threshold of TPs, rather than being part of a continuum.
1. Introduction
Fibromyalgia is a characterized subgroup of patients present-
ing with chronic widespread pain (CWP) and widespread
mechanical hyperalgesia. These characteristics are enshrined
in the 1990-ACR criteria [1] that have been the cornerstone
for research studies of the past 2 decades. Contemporary
research in subjects fulfilling 1990-ACR criteria has provided
persuasive evidence for augmented central pain processing in
terms of sensitization of nociceptive neurons and ascending
spinal tracts accompanied by dysfunction of descending pain
inhibitory pathways [2]. The underlying pain mechanisms in
subjects with CWP with fewer than 11 tender points (TP)
are less well described [2]. Mechanical hyperalgesia is a
clinical manifestation of central sensitization and, although
an imperfect measure, the manual TP examination has been
considered a primary identifier of pain hypersensitivity [3–
6]. In the development of the 1990 ACR classification criteria
for fibromyalgia, TPs were found to be the most powerful
discriminator between fibromyalgia and control subjects;
the best separation occurred at about the 13 TPs for mild
tenderness (the subject state that palpation is painful) and
about 6 TPs for moderate or greater tenderness (the pain
complaint is accompanied by facial expression and/or flinch
at palpation) [1]. In the clinical context, the 1990-ACR criteria
cutoff at 11 TPs, based on a score ofmild or greater tenderness,
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has been criticized for placing a diagnosis of fibromyalgia at
the far end of a severity spectrum and for ignoring other key
symptoms [7–9]. This has led to the suggestion of diagnostic
criteria based on pain and typical fibromyalgia symptoms,
but omitting the evaluation of mechanical hyperalgesia [9].
Influential in the development of these new symptom-based
diagnostic criteria is the argument that fibromyalgia is best
understood as part of a polysymptomatic distress continuum
and not as a categorical disorder. A contrary opinion is that
fibromyalgia is both a categorical disorder and the end of a
continuum of pain processing [10].
A positive relationship between TP count (TPC) and
psychological distress seems well established, although a
quite variable association between the TPC and clinical
disease severity has been reported [11–15]. In these studies
clinical disease severity has been defined in differentways and
only a minority has included patients with CWP and fewer
than 11 TPs or disease variables derived from observation-
based assessment.
The WHO international classification of functioning,
disability, and health (ICF) can serve as a framework when
defining clinical disease severity [16]. The ICF conceptualize
health and health-related states as a complex interplay of the
following health components: body functions and structures
(including mental functions), activities (execution of tasks)
and participation (involvement in life situations), and envi-
ronmental and personal factors. Based on the ICF, interna-
tional recommendations for a number of musculoskeletal
pain disorders have been developed [17], including definition
and validation of ICF core sets for patients with CWP [18–
23]. ICF core sets represent a selection of ICF categories
relevant for specific conditions and serve as standards for
the multidimensional assessment of patients for clinical
encounters and trials.
The objective of this studywas to evaluate the relationship
between TPC threshold and clinical disease severity in
patients with CWPusing themultidimensional ICFmeasure-
ment framework. It was hypothesized that the clinical disease
burden in patients with CWP would be influenced by the
presence and spread of mechanical hyperalgesia, as evaluated
by the manual TP examination.
2. Methods
2.1. Study Design and Setting. The study was cross-sectional
with systematic data collection on consecutive female
patients diagnosed with CWP at rheumatologic examination
and accepted for enrolment in an interdisciplinary reha-
bilitation program tailored for this patient population at
the department of rheumatology, Frederiksberg Hospital. A
comprehensive baseline assessment based on the brief ICF
core set for CWP [18] was implemented. Several self-report
and observation-based assessment tools were applied in the
data collection and data stored in a clinical database. Data
were obtained in a two-year period from 1 March, 2007, to
28 February, 2009. All examination methods were approved
by the local ethics committee (KF 01-045/03).
2.2. Participants. The referral diagnosis of CWP was based
on the 1990-ACR definition of wide spread pain (i.e., patient
reporting of pain axially and in minimum 3 body quadrants)
[1] and the diagnostic assessment prior to referral included
a full rheumatologic examination and extensive blood test
screening. Exclusion criteria were need of assistance in
personal activities of daily living, concurrent history of major
psychiatric disorder not related to the pain disorder, and
other medical conditions capable of causing patients symp-
toms (e.g., uncontrolled inflammatory/autoimmune disor-
der, uncontrolled endocrine disorder, malignancy, etc.). All
patients continued usual medication including analgesics.
2.3. Data Sources and Measurements. The brief ICF core set
for CWP and applied instruments classified according to the
dimensions of the ICF model are presented in Table 1.
2.3.1. Patient-Reported Outcomes (PRO). PRO were based
on validated self-administered questionnaires. For some
of the applied instruments content comparison and
linkage with ICF categories have been reported in the
literature [22]. Detailed descriptions are enclosed in
Annex A (see Supplementary Material available online
at http://dx.doi.org/10.1155/2014/417596). Additional data
regarding health and personal and environmental factors
were collected using a standardized basic information
questionnaire (BIQ), for example, employment status, use of
social security and health care services, pain medication, and
family relationships.
2.3.2. Observation-Based Outcomes
Manual TP Examination and TPC. TPs were assessed both
for number and severity of mechanical hyperalgesia as
described in the 1990-ACR guidelines [1]. Digital pressure of
approximately 4 kg was applied at each of the 18 predefined
TP sites, and the patient’s pain response at each site was
scored as 0 = no pain, 1 = mild pain (complaint of pain
without grimace, flinch, or withdrawal), 2 = moderate pain
(pain plus grimace or flinch), and 3 = severe pain (pain plus
marked flinch or withdrawal). As the primary goal of this
study was to evaluate the relationships between mechanical
hyperalgesia and disease severity, a mild pain response (i.e.,
1) was considered potentially ambiguous and the cutoff
response was therefore set at ≥2. All TP examinations were
performed by experienced and calibrated raters.
Assessment of Motor and Process Skills (AMPS). The AMPS
is a standardized observation-based assessment instrument
that incorporates the use of Rasch analysis providing equal-
interval linear measures of the quality of ADL task per-
formances [24, 25]. Two domains of ADL performance are
evaluated: ADL motor skills (moving self and objects) and
ADL process skills (organizing and adapting actions). Several
studies support good test-retest and rater reliability as well
as validity of the AMPS including in CWP populations [26].
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Table 1: Instruments classified according to the ICF core sets for
CWP.
ICF core sets for CWP Instruments in this study
Body functions
Emotional functions GAD-10, MDI, SF-36, FIQ
Sensation of pain FIQ, SF-36
Exercise tolerance functions Mob-T
Psychomotor functions FIQ, SF-36
Control of voluntary movement
functions AMPS motor
Energy and drive functions Mob-T, SF-36, FIQ
Sleep functions FIQ
Content of thoughts CSQ
Muscle power functions Grippit, LIDOMulti Joint
Attention function AMPS process
Activity and participation
Carrying out daily routines AMPS, FIQ, SF-36
Handling stress and other
psychological demands CSQ
Family relationships SF-36
Remunerative employment FIQ, BIQ
Intimate relationships
Walking 6-MW
Recreation and leisure SF-36
Solving problems AMPS process, CSQ
Lifting and carrying objects AMPS motor
Doing housework AMPS, FIQ
Environmental factors
Drugs BIQ
Immediate family BIQ
Health professionals BIQ
Individual attitudes of immediate
family members
Social security services, systems,
and policies BIQ
Individual attitudes of friends
GAD-10: generalized anxiety disorder;MDI:major depression inventory; SF-
36: short-form-36 health survey; FIQ: fibromyalgia impact questionnaire;
CSQ: coping strategy questionnaire; AMPS: assessment of motor and
process skills; 6-MW: 6-minute walk; Mob-T: mobility tiredness; BIQ: basic
information questionnaire.
AMPS evaluations were performed by trained and calibrated
AMPS raters.
Assessment of Pressure PainThreshold and Tolerance. Pressure
pain sensitivity was determined on the lower leg using com-
puterized cuff pressure algometry (CPA).The setup consisted
of a pneumatic tourniquet cuff, a computerized compressor,
and an electronic 10 cm visual analogue scale (VAS). Double-
chambered textile tourniquet cuffs (VBM Medizintechnik
GmbH, Sulz, Germany) were used for pressure application
[27].The following parameters were determined: pain thresh-
old defined as the pressure of the cuff at the subject’s first
sensation of pain when applying a constantly raising pressure
(Unit kPa); pain tolerance defined as the pressure of the cuff
when the pressure is switched off by the patient due to worst
tolerable pain caused by pressure stimulation (Unit kPa).
Reduced pressure-pain thresholds assessed byCPAhave been
demonstrated in patients with fibromyalgia and reported not
to be influenced by psychological distress, indicating that this
method may be used for objective assessment of deep tissue
pain hypersensitivity [28].
Baseline assessment also includedmeasurements of max-
imal isokinetic knee muscle strength, maximal grip strength,
and a 6-minute walk test (see Annex A).
2.4. Statistical Methods and Threshold Definition. Disease
variables classified according to the ICF are presented as
mean, standard deviation (SD), range, and number of people
in the study population. Differences between groups were
assessed using analysis of variance (𝑧-test), with significance
level 0.05.
Three different statistical models were applied in the
multivariate analyses. First, TPC were analyzed with a
logistic regression model, allowing the TPC to depend on
the included disease variables from the ICF-measurement
framework (the continuum model).
Secondly, each possible value for the TPC except the
biggest possible (i.e., 1–17) was considered a threshold, with
possibly different disease severity for patients with TPC above
and below the threshold. For each threshold 𝑖, it was recorded
for each person in the study population whether TPC was
bigger than 𝑖 or not, and the results were analyzed with
logistic regression models. In these analyses, two types of
logistic regression models were applied: one model type was
carried out for each single covariate, with only the given
covariate considered as an explanatory variable (the univari-
ate/marginal model) and the other model simultaneously
considered all covariates in a multiple logistic regression
model (the multivariate/full model). These two models were
used in order to uncover whether the covariate was associated
with a TPC above i, either marginally/in its own respect or
in full/considered simultaneously with other covariates, and
would implicate that a TPC above 𝑖would give a different level
of disease severity than a TPC below or equal to i, within the
ICF framework. Significance of all covariates was considered
throughmodel reduction. Tests were performed as likelihood
ratio tests evaluated with a Chi-square distribution. The
statistical significances were tabled as a function of the
threshold level and reported as either insignificant or with
three varying degrees of significance. In the full model, the 𝑃
values for nonsignificant factors were calculated by adding it
to the reducedmodel andperforming the significance test. All
logistic regression analyses were carried out using the Splus
software, version 6.2 (Insightful Corp. 2003).
3. Results
3.1. Participants. In the study period, 274 female patients
were referred for rehabilitation. Three were excluded due
to lack of a sufficient TP examination. This resulted in a
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study sample of 271 females diagnosed with CWP (1990-
ACR definition) and evaluated before enrolment in the
rehabilitation program. Due to the large number of variables,
it was not possible to obtain complete datasets on all patients.
Number of patientswithmissing values can be extracted from
Table 2.
3.2. Descriptive Data. Demographic data and key variables
classified according to the ICF from the overall study popula-
tion are presented in Table 2. Setting the TPC pain response
cutoff at 1 (mild pain), the median TPC was 18 (range 5–
18) and 265 participants (97.8%) had a TPC of ≥11, that is,
fulfilling the 1990-ACR criteria for fibromyalgia. Setting the
TPC pain response cutoff at 2 (moderate pain), the median
TPC was 14 (range 0–18) and 256 participants (94.5%) had a
TPC of ≥6 TPs, that is, fulfilling the criteria for fibromyalgia
based on the requirement of a moderate or greater pain
response at palpation (Figures 1 and 2in Annex A show the
number of patients at each TPC with a pain response cutoff
set at 1 and 2, resp.).
3.3. Threshold Analyses and Multiple Logistic Regression
Analyses. The three different multivariate models showed
different strength of relationship between variables and
number of TPs. In the first model (the continuum model),
none of the included variables from the ICF-measurement
framework reached a significance level above 0.05 with the
TPC established at either of the TPC pain response cutoffs.
Results from the univariate/marginal model, where only
the given covariate was considered as explanatory variable,
and with the TPC pain response cutoff set at 1 and 2,
respectively, are presented in Tables 3 and 4. Setting the
pain response cutoff at 1, threshold analysis in the univari-
ate/marginal model revealed only a few scattered signifi-
cances in the higher end of the TPC threshold spectrum
(Table 3). The multivariate/full model did not function for
a TPC established at a pain response cutoff at 1. For some
thresholds, no interpretable model could be identified, and
in the area where marginal significances were present for
more than a few covariates (TPC threshold values 14–17), the
significances were few and mostly with weak significances
(i.e., 𝑃 > 0.01).
With the TPC pain response cutoff set at 2, TPC thresh-
olds ≥8 were associated with a large number of consistently
significant covariates related to pain and pain-related inter-
ference with everyday life (Figure 1). At TPC thresholds of
1–7 only a few significant covariates were seen and only the
ADL motor ability measure of the AMPS was consistently
significant.
A notable feature of the results of the univariate/marginal
model with the TPC pain response cutoff set at 2 (Table 4)
was that as the TPC threshold increased, all covariates were
either consistently nonsignificant, only scattered significant,
or reached a threshold from where they became consistently
significant.
This was in contrast to the analysis with the TPC
pain response cutoff set at 2 in the multivariate/full model
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Figure 1: Number of significant covariates versus tender point count
(TPC) thresholds, varying between 1 and 17 and with the pain
response cutoff set at 2 at the tender point examination. Analyzed
in the univariate/marginal model a large number of variables linked
to pain and pain-related functional interference (summarized in
Table 4) appeared as consistently significant explanatory factors
from a TPC threshold at 8, indicating a perturbation of clinical
disease severity at this threshold.
(Table 5), where all covariates were considered simultane-
ously. Due to the high number of variables and a relatively
small number of patients with a low TPC, this model
could only handle TPC thresholds of 6 and above. For
TPC thresholds of 6 and 7, three covariates (FIQ stiffness,
AMPS ADL motor ability, and SF-36 social functioning) were
consistently significant. At the TPC threshold of 8, five
new covariates (total FIQ score, FIQ restorative sleep, FIQ
well-being, NSAID use, and BIQ work interference) entered
the model; 4 of them were consistently significant for the
next three TPC thresholds when sequentially increasing the
threshold value by 1. These covariates, significant for TPC
thresholds between 8 and 11, remained significant in the
marginal model for higher thresholds, while replaced by
other covariates as explanatory variables in the full model.
A similar shift was seen for TPC thresholds above 15. These
two shifts were comparable to the noted shifts in themarginal
model, but where the results in the marginal model were
more consistently significant variables, the shift in the full
model indicated a change in explanatory variables. Notably,
the covariates social functioning and self-reported change or
disability from usual working activity entered the full model as
significant explanatory variables at TPC thresholds between
6 and 10, while they were without individual significance in
the marginal model.
3.4. Comparison between Groups. Based on the results of the
regression analyses with the TPC pain response cutoff set
at 2, differences between groups were assessed for the TPC
threshold of 8 (Table 6).
Within the body domain, patients with a TPC above 8
reported significantly higher levels of pain intensity, tired-
ness, fatigability, and muscle stiffness and had lower levels of
knee muscle strength and walking ability (6-MW) and lower
International Journal of Rheumatology 5
Table 2: Demographic data and key variables classified according to the ICF model.
Mean SD Range 𝑁
Demographics
Age (years) 45.5 9.66 20.4–71.5 271
Symptom duration (months) 122 102 6–540 227
Body mass index (BMI) 26.9 5.5 16.9–45.7 270
Never Sometimes Daily 𝑁
Pain medication
Weak analgesics 3% 63% 34% 237
NSAID’s 39% 43% 18% 230
Opioids 56% 23% 21% 231
Yes No 𝑁
Antidepressants 31% 69% 237
Pain-related work interference
Changes or permanent disability from usual working activity due to pain 82% 18% 235
Applied for permanent disability pension at some stage 25% 75% 231
Currently holding a position or enrolled in education 21% 239
Currently on long-term sick leave 25% 239
Currently receiving social benefits or socials services of some sort 34% 239
Mean SD Range 𝑁
Body
Muscle strength UE (PTQ extension) 84.94 36.88 7–199 249
Muscle strength UE (PTQ flexion) 40.23 18.41 5–85 249
Grip strength, max. 174.96 82.24 8–408 258
Vitality (SF-36) 21.88 17.26 0–75 268
Fatigue (FIQ) 8.01 1.95 1.3–10 267
Rest (FIQ) 7.57 2.33 0–10 266
Well-being (SF-36) 55.62 20.61 0–100 268
Well-being (FIQ) 7.32 2.66 0–10 258
Anxiety (FIQ) 4.46 3.43 0–10 267
Anxiety (GAD-10) 19.17 9.78 1–50 268
Depression (FIQ) 3.81 3.42 0–10 268
Depression (MDI) 21.60 10.68 3–50 268
Bodily pain (SF-36) 24.07 15.03 0–84 268
Pain intensity (FIQ) 7.07 1.95 0–10 268
Muscle stiffness (FIQ) 6.25 2.75 0–10 265
Tiredness mobility (Mob-T) 1.68 1.61 0–6 257
Pain detection threshold (PDT) 12.16 7.52 0.3–46.2 229
Pain tolerance threshold (PTT) 31.65 14.73 9.2–86.7 229
Activity and participation
ADL ability motor (AMPS) 1.07 0.50 0.4–2.82 257
ADL ability process (AMPS) 1.09 0.35 0.12–2.18 257
Walking speed (6-MW) 449.67 114.37 94.6–712.1 259
Activity limitations (FIQ) 5.24 2.22 0–9 267
Physical functioning (SF-36) 42.88 20.01 0–95 268
Role physical (SF 36) 9.71 21.03 0–100 267
Role emotional (SF-36) 45.12 43.30 0–100 263
Social functioning (SF-36) 48.04 26.47 0–100 268
Days of sick leave pr. week (FIQ) 1.12 1.68 0–6 70
Work ability (FIQ) 6.62 2.50 0–10 72
Personal
Catastrophizing (CSQ) 15.91 8.35 0–36 266
Perceived control over pain (CSQ) 2.40 1.38 0–6 266
Ability to decrease pain (CSQ) 2.28 1.22 0–6 264
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Table 2: Continued.
Mean SD Range 𝑁
Global measures
FIQ total 61.32 18.53 2.9–97.4 268
SF-36 PCS 26.95 6.68 8.8–50.7 268
SF-36 MCS 40.68 11.96 14.9–66.6 268
General health (SF-36) 31.60 18.15 0–97 267
GAD-10: generalized anxiety disorder; MDI: major depression inventory; SF-36: short-form-36 health survey; FIQ: fibromyalgia impact questionnaire; SF-36
PCS: SF-36 physical composite score; PTQ: peak torque; SF-36 MCS: SF-36 mental composite score; CSQ: coping strategy questionnaire; AMPS: assessment
of motor and process skills; 6-MW: 6-minute walk; Mob-T: mobility tiredness.
pressure pain thresholds as measured with CPA. However,
CPA pain thresholds overall showed only a weak correlation
with the number of TPs [pain threshold: 𝑟 = 0.291, 𝑃 = 0.01;
pain tolerance: 𝑟 = 0.298, 𝑃 = 0.01]. Measures of psycholog-
ical distress (anxiety, depression, and pain catastrophizing)
were low to moderate in the overall study population and no
significant group differences were present.
Within the domain of activity and participation, the TPC
threshold of 8 or more was associated with significantly
higher self-reported ratings of functional disability and also
ADL motor ability measures of the AMPS were significantly
lower in patients with a TPC above 8 [1.04 versus 1.29 logits,
𝑃 = 0.004], indicating a higher degree of observable effort
and/or fatigability during ADL-task performance. No signif-
icant differences between groups were noted for measures
relating to the level of participation (e.g., self-reported social
functioning or work ability) or personal factors (e.g., ability
to reduce or control pain) at this TPC level.
4. Discussion
This study provides evidence for a positive relationship
between the number of TPs, defined by a moderate or
greater pain response to palpation, and disease severity in
patients with CWP. Notably, disease expression and TPs at
this pain response cutoff were related through a threshold on
the number of TPs rather than being part of a continuum.
Logistic regression analyses indicated that a TPC of 8 defined
a threshold above which a large number of variables linked to
pain and pain-related interference with everyday life became
consistently significant explanatory factors (Figure 1).
4.1. TPC Threshold Analyses. The manual TP examination
represents onemethod for evaluating the presence and spread
of mechanical hyperalgesia [4]. The finding of a positive
relationship between a high number of TPs and symptom
severity suggests that awidespread distribution ofmechanical
hyperalgesia influences the expression of clinical symp-
toms. Notably, we did not find any statistically significant
explanatory variables in the continuum model, suggesting
that clinical covariates do not impact continuously on TPC
throughout its range but, rather, in concentrated intervals,
in a way that would not be captured by the continuum
model. Thus, these results support the notion that disease
severity and TPs in patients with CWP are related through
a threshold on the number of TPs. A graphic representation
of this relationship is seen in Figure 1, which provides a direct
visualization that the disease severity does not vary much for
TP thresholds less than 8. However, adding another TP to the
threshold has a much bigger impact in the interval 8 to 9 TPs
compared to the interval 4 to 5 TPs. Therefore, the impact
of TP count on disease severity is different between these
two intervals, supporting the conclusion that TPC variation
should be considered locally (i.e., around a threshold) rather
than in a continuum.
Based on the requirement of a moderate or greater pain
response at palpation, analyses in the univariate/marginal
model showed that a large number of variables from the ICF
measurement framework emerged as consistently significant
explanatory factors at a TPC threshold ≥8, indicative of
a pronounced shift in disease severity at this threshold.
The first group of covariates to enter the model was PROs
mainly related to pain, fatigue, stiffness, and functioning
followed by observation-based measures of muscle strength
and walking ability, which appeared at a TPC threshold of
11. The last group of covariates, entering the model at a TPC
threshold at 15, were psychological distress variables (anxiety
and depression) and self-reported well-being measured with
the SF-36. None of these variables appeared as significant
explanatory factors at lower TPC thresholds and pain catas-
trophizing and pain self-efficacy variables never entered the
model. This finding was in accordance with the results of
the multivariate/full model and supports the notion that the
relationship between psychological distress and CWP is not
solely due to TPs, but most likely pertains to the affective
component of pain.
It is noteworthy that in the univariate/marginal model
onlythe ADL motor ability measure of the AMPS was
consistently significant throughout the entire range of TPC
thresholds. Functional ability is considered a core outcome
in clinical pain research [18, 29–31]. A substantial negative
impact of CWP on ADL motor ability as measured with
the AMPS has been observed in our study population [32].
However, assessment of pain-related interference with func-
tioning is complex and several studies have demonstrated a
poor correlation between patient-reported and observation-
based assessment of functional ability in patientswith chronic
pain conditions including CWP [26, 33, 34]. Analyzed in
the univariate/marginal model, a significant relationship
betweenTPCand self-reported physical functioningwas only
demonstrated from a TPC threshold at 8 and above. This
finding emphasizes that self-reported and observation-based
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Table 6: Variables classified according to the ICF model. Differences between groups at a tender point threshold level at 8 with the pain
response cutoff set at 2 at the tender point examination.
Outcome variable TPC: 0–8 TPC: 9–18 𝑃 value
Mean (SD) Range Mean (SD) Range
Body
Muscle strength UE (PTQ extension) 96.8 (30.6) 38–160 83.0 (37.5) 7–199 0.04
Muscle strength UE (PTQ flexion) 46.6 (17.9) 18–85 39.2 (18.3) 5–84 0.026
Grip strength, max. 192.5 (63.61) 76–304 172.2 (84.6) 8–408 0.176
Vitality (SF-36) 26.3 (16.9) 0–70 21.2 (17.2) 0–75 0.105
Fatigue (FIQ) 7.3 (2.2) 1.3–10 8.1 (1.9) 1.4–10 0.014
Rest (FIQ) 6.5 (2.5) 0.6–10 7.7 (2.3) 0.1–10 0.005
Well-being (SF-36) 55.2 (20.4) 20–92 55.7 (20.7) 0–100 0.904
Well-being (FIQ) 6.6 (2.6) 0–10 7.5 (2.7) 0–10 0.079
Anxiety (FIQ) 3.9 (3.6) 0–10 4.5 (3.4) 0–10 0.328
Anxiety (GAD-10) 17.3 (9.4) 3–42 19.5 (9.8) 1–50 0.217
Depression (FIQ) 4.3 (3.4) 0–10 3.7 (3.4) 0–10 0.348
Depression (MDI) 21.1 (10.7) 5–45 21.7 (10.7) 3–50 0.763
Bodily pain (SF-36) 29.1 (12.3) 0–60 22.3 (15.3) 0–84 0.034
Pain intensity (FIQ) 6.4 (1.9) 1.5–9.5 7.2 (1.9) 0–10 0.021
Muscle stiffness (FIQ) 4.8 (2.9) 0–9.8 6.5 (2.7) 0–10 0.001
Tiredness mobility (Mob-T) 2.4 (1.8) 0–6 1.5 (1.6) 0–6 0.009
Pain detection threshold (PDT) 15.0 (8.4) 4.2–46.2 11.7 (7.2) 0.7–42.5 0.02
Pain tolerance threshold (PTT) 37.1 (14.2) 12.3–72.8 30.7 (14.6) 9.2–86.7 0.019
Activity and participation
ADL ability motor (AMPS) 1.29 (0.49) 0.11–2.45 1.04 (0.49) 0.04–2.82 0.004
ADL ability process (AMPS) 1.16 (0.37) 0.53–1.86 1.08 (0.34) 0.12–2.18 0.204
Walking speed (6-MW) 487.5 (127.3) 142–672 443.8 (111.4) 95–712 0.035
Activity limitations (FIQ) 4.2 (2.3) 0–8.7 5.4 (2.2) 0–9 0.003
Physical functioning (SF-36) 50.8 (19.3) 10–85 41.7 (19.9) 0–95 0.012
Role physical (SF 36) 8.6 (20.14) 0–75 9.9 (21.2) 0–100 0.733
Role emotional (SF-36) 41.2 (41.9) 0–100 45.7 (43.6) 0–100 0.57
Social functioning (SF-36) 52.1 (27.0) 12.5–100 47.4 (26.4) 0–100 0.326
Days of sick leave pr. week (FIQ) 0.89 (1.3) 0–2.9 1.2 (1.7) 0–5.7 0.685
Work ability (FIQ) 5.7 (2.8) 1.4–8.2 6.8 (2.5) 0–10 0.218
Personal
Catastrophizing (CSQ) 15.3 (8.3) 0–33 16.0 (8.4) 0–36 0.628
Perceived control over pain (CSQ) 2.6 (1.4) 0–5 2.4 (1.4) 0–6 0.354
Ability to decrease pain (CSQ) 2.5 (1.4) 0–5 2.3 (1.2) 0–6 0.284
Global measures
FIQ total 54.4 (18.59) 14.8–92.1 62.3 (18.4) 2.9–97.4 0.018
SF-36 PCS 29.7 (7.0) 15.8–43.8 26.5 (6.6) 8.8–50.7 0.01
SF-36 MCS 40.1 (12.6) 20.4–64.3 40.8 (11.9) 14.9–66.6 0.773
General health (SF-36) 34.1 (15.6) 5–77 31.2 (18.5) 0–97 0.4
GAD-10: generalized anxiety disorder; MDI: major depression inventory; SF-36: short-form-36 health survey; FIQ: fibromyalgia impact questionnaire; SF-36
PCS: SF-36 physical composite score; PTQ: peak torque; SF-36 MCS: SF-36 mental composite score; CSQ: coping strategy questionnaire; AMPS: assessment
of motor and process skills; Mob-T: mobility tiredness; 6-MW: 6-minute walk.
assessment of functioning may evaluate different aspects of
functional ability and the AMPS may prove to be a sensitive
and valuable core instrument in the outcome assessment of
patients with CWP, particularly at the lower end of the TP
spectrum.
TPC threshold analyses in the multivariate/full model
with the TPC pain response cutoff set at 2 indicated a
shift in explanatory variables similar to the shifts in the
univariate/marginal model and at the same thresholds.
However, whereas the results in the marginal model were
more consistently significant, the behavior of the full model
suggested a change in explanatory variables.The results of the
multivariate/full model indicated that at lower TPC thresh-
olds covariates related to function (the ADL motor ability
International Journal of Rheumatology 11
measure of the AMPS, muscle stiffness, social functioning,
and work interference) seemed to show the strongest and
most consistent relationshipwith number of TPs. Contrary to
the findings in the univariate/marginal model, self-reported
level of pain and fatigue never entered the full model
as significant explanatory factors. Pain reduction following
treatment has been shown to parallel improvements in other
outcomes in patients with CWP, including self-reported
physical and social functioning, sleep, and interference with
work [35].The interaction between TPC, pain, and functional
ability is probably multifaceted. Our results indicate that
functional ability, whether related to ADL performance
or working ability in the multivariate context, provides a
stronger correlation to TPC than level of pain. Equivalent
to the univariate/marginal model, the next shift in the full
model took place for the TPC threshold of 11; the strongest
and most consistent relationship now seemed to be with pain
threshold measured by CPA. The last shift took place at the
TPC threshold of 15; here psychological distress variables
including ability to reduce pain, pain tolerance, and self-
reported tiredness related to mobility entered the model. The
latter has been shown to be an early indicator of later disability
and use of social and health services among the elderly [36].
At a TPC threshold ≥11 the full model indicated a strong
relationship between pressure pain sensitivity, as measured
by CPA and number of TPs. However, there was only a
weak correlation between CPA and number of TPs, implying
that they probably measure different aspects of mechanical
hyperalgesia.
Several studies have reported a positive relationship
between number of TPs and self-reported somatosensory
symptoms of neuropathic pain in patients with CWP and
fibromyalgia [37–39], as well as a positive correlation between
neuropathic pain symptoms and pressure pain thresholds
measured by CPA [40]. A high TPC or reduced pressure pain
threshold, as measured by CPA, points to a predominantly
central pain mechanism in CWP pathophysiology. Since
somatic and central pain disorders entail different pain
management strategies, the identification of augmented pain
processing has important implications for therapy. Char-
acterization of patients with CWP, based on the presence
and spread of mechanical hyperalgesia, whether assessed
by manual TP examination or CPA, may therefore assist
in advancing a more individualized and pain mechanism
focused treatment in the clinical setting.
4.2. Comparison between Groups. Evaluated in an ICF-
measurement framework covering core set categories iden-
tified for the multidimensional assessment of CWP, the neg-
ative impact on measures obtained at the body level and level
of activity and participation was substantial. In accordance
with the existing literature [41, 42] the results of the study
supported a considerable heterogeneity with regard to disease
manifestations, as reflected in the observed wide range of
scores on key outcomemeasures. Confirming our hypothesis,
patients with a high TPC based on a TPC pain response
cutoff set at 2 showed higher levels of clinical pain, muscle
stiffness, tiredness, fatigability, and interference with func-
tional ability than patients with a lower TPC. Setting the TPC
threshold at 8 yielded significant differences in observation-
based tests assessing body functions, including measures
of pressure pain thresholds, muscle strength, and walking
ability, as well as observation-based assessment of ADL task
performancemeasuredwith theAMPS.No in-between group
differenceswere present inmeasures covering the ICF-level of
participation, for example, self-reported social functioning or
work interference or in psychological distress variables and
pain self-efficacy variables at the TPC threshold level of 8,
indicating that the pain condition itself and not concomitant
psychological distress more likely explained the observed in-
between group difference of disease impact.
Limitations and Generalizability.The study was conducted in
a specialized tertiary-care setting and patients encountered
are not necessarily representative of patients from the overall
referral population. It has been reported that patients with
CWP in referral clinics demonstrate higher pain severity and
negative consequences related to pain than similar patient
groups found in the community [43]. However, our patient
population seems representative of patients encountered in
the clinic setting based on the obtained disease severity
scores. Reflecting recruitment from a tertiary-care setting
only a relatively small number of patients had very few TPs.
This influenced the analyses in the multivariate/full model,
which could only handle TPC thresholds from 6 and above
due to a high number of variables. Finally, the study was
limited by only including women. As the prevalence of CWP
is higher in women than in men [44] the study results still
seem relevant for the CWP population.
5. Conclusions
Patients with CWP encountered in the clinical setting exhibit
a positive relationship between the number of TPs and sever-
ity of the clinical pain condition through a TPC threshold
rather than a TPC continuum. Provided the requirement
of a moderate or greater pain response at palpation, the
major shift of disease severity occurred at a TPC of ≥8.
This relationship was not observed if the TPC in individual
patients was based on a TP cutoff set at mild tenderness,
suggesting that a hyperalgesic pain response at palpation
should be required in order for TPs to be considered a
primary identifier of pain hypersensitivity. These findings
are at odds with the affective spectrum disorder hypothesis
[7] and support the premise that the presence and spread
of pressure pain hyperalgesia influences symptomatology in
CWP.How to classify or diagnose fibromyalgia is still amatter
of debate. Using a TP cutoff at 8, based on the requirement of
a moderate or greater pain response at clinical examination,
could assist the identification of patients with CWP and
a more severe pain condition, which could be labeled as
fibromyalgia. Overall, this study supports the continued
use of the manual TP examination as a valid measure of
pain hypersensitivity and abnormal pain processing in the
clinical setting and underlines the need for a comprehensive
12 International Journal of Rheumatology
evaluation in all patients with CWP with a view to early and
targeted intervention.
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